Daniel S Dickerson MD PhD, FAAFP

Medical Director / Principal Investigator Phase 1 & Phase 2 Clinical Research Trials

9755 Ridge DrLenexa, KS 66219
Phone+1 913-410-2973
Fax+1 913-599-2753

Dr. Dickerson is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Dickerson's full profile Already have an account?

Summary

Dr. Daniel Dickerson is a medical professional based in Lenexa, KS, with a specialty in research and substantial experience in family medicine. He holds an MD from the University of Kansas School of Medicine and a PhD in Chemistry-Biochemistry from the University of Missouri. His career includes roles as Medical Director/Principal Investigator at ICON Clinical Research since 2014, Clinical Instructor at the University of Kansas School of Medicine, and a Family Physician at both LMH Health and AdventHealth Shawnee Mission. Dr. Dickerson has experience in conditions like atherosclerosis, diabetic neuropathy, Alzheimer's disease, COPD, and cystic fibrosis. He has authored several research publications on topics including pharmacokinetics and pharmacodynamics and has been involved in multiple clinical trials. His accolades include awards such as the Rainbow Award, Preceptor of the Year, and Teacher Development Award.

Education & Training

University of Kansas School of MedicineResidency, Family Medicine, 1996 - 1999
University of Kansas School of MedicineClass of 1996
University of MissouriPhD, Chemistry-Biochemistry, 1987 - 1994

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

KS State Medical License 1999 - 2027

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification PowerChart (Clinical), Cerner Corporation, 2012-2015
CMS Meaningful Use Stage 1 Certification PowerChart (Clinical), Cerner Corporation, 2012-2015
CMS Meaningful Use Stage 1 Certification PowerChart (eRx), Cerner Corporation, 2012-2015

Clinical Trials

Bioequivalence of Duvelisib and Food Effect on Pharmacokinetics of IPI-145
COMPLETED
PHASE1
Study of PF614 Compared to OxyContin® in Healthy Volunteers (PF614-101) Start of enrollment: 2016 Nov 16
COMPLETED
PHASE1
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-D4010 in Healthy Subjects
COMPLETED
PHASE1

Publications & Presentations

PubMed

First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-986308: A Renal Outer Medullary Potassium Channel Inhibitor.
Sharif I Soleman, Juan Maya, Paul Levesque, Atif Mohammad, Lisa Christopher
Clinical Pharmacology and Therapeutics. 2024-12-01
6 citations
Clinical pharmacology and tolerability of REC-994, a redox-cycling nitroxide compound, in randomized phase 1 dose-finding studies.
Ron Alfa, Timothy Considine, Shafique Virani, Matt Pfeiffer, Anthony Donato
Pharmacology Research & Perspectives. 2024-06-01
6 citations
A Randomised Controlled Trial Comparing the Pharmacokinetics and Tolerability of the Proposed Adalimumab Biosimilar MSB11022 Delivered via Autoinjector and Pre-filled ...
Ahad Sabet, Daniel S Dickerson, Eugenia E Kunina, Anna Lucia Buccarello, Joëlle Monnet
Rheumatology and Therapy. 2022-04-01

Committees

Chairman, Kansas Academy of Family Physicians Governmental Advocacy Committee 2015 - 2020
School Board Member, Eudora Board of Education 2011 - 2015
Chief of Family Medicine, Lawrence Memorial Hospital Executive Committee 2005 - 2009